Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus

Lupus. 2008 Jan;17(1):69-71. doi: 10.1177/0961203307083479.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • ADAM Proteins / blood
  • ADAMTS13 Protein
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Lupus Erythematosus, Systemic / blood
  • Lupus Erythematosus, Systemic / complications*
  • Lupus Erythematosus, Systemic / drug therapy
  • Middle Aged
  • Purpura, Thrombotic Thrombocytopenic / blood
  • Purpura, Thrombotic Thrombocytopenic / diagnosis
  • Purpura, Thrombotic Thrombocytopenic / drug therapy*
  • Purpura, Thrombotic Thrombocytopenic / etiology
  • Recurrence
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human